Pioneering Advances in Biotechnology
- Empowering quality of life thru innovative scientific paradigms
Pioneering Advances in Biotechnology
- Empowering quality of life thru innovative scientific paradigms
Dr.Mark McCaulley
Curriculum vitae summary
Medical school:
University of Illinois College of Medicine, Chicago, IL, 1975 to 1979, MD
Residency:
Denver Presbyterian Medical Center, Denver, CO, 1979 to 1982, Internal Medicine
Medical licensure:
Colorado
Board Certification:
ABIM, September 15, 1982
Present position:
Private practice general internal medicine 1982-2023
Independent unaffiliated researcher in neurodevelopmental diseases and in Alzheimer's Disease 2015-present
Academic rank:
Assistant Clinical Professor of Medicine, retired, 2023 to present
Assistant Clinical Professor of Medicine, 2001 to 2023,
University of Colorado School of Medicine
Teaching activities:
Clinical instruction of medical students, 1990 to 2023, University of
Colorado School of Medicine
Honors and awards:
Clinical faculty medical student teacher of the year, 2001, University of Colorado School of Medicine
Outstanding contribution by a rural internist, 2006, University of Colorado School of Medicine
Teaching in Excellence Award 2005-2006, University of Colorado School of Medicine, presented by the classes of 2006 and 2007
Doc Willett Award, the outstanding medical professional award 2012, Yampa Valley Health Care Foundation
Bibliography
- Long-term clinical outcomes of Lyme disease. Annals of Internal Medicine, 1995 Jun 15; 122(12):961.
- Immunethrombocytopenia and ulcerative colitis: Response to nonoperative therapy. Journal of Clinical Gastroenterology, 1996 Oct; 23(3):242-3.
- The costs of Lyme disease. Archives of Internal Medicine, 1997 Apr 14; 157(7):817-8.
- Guidelines for the clinical diagnosis of Lyme disease. Annals of Internal Medicine, 1998 Sep 1; 129(5):422-3.
- Treatment of patients with persistent symptoms and a history of Lyme disease. New England Journal of Medicine, 2001 Nov 8; 345(19):1424.
- Suction tenting for polypectomy. McCaulley ME. Gastrointestinal Endoscopy, 2014 Sep; 80(3):538-9. https://doi.org/10.1016/j.gie.2014.04.002
- Alzheimer's Disease: Exploring the Role of Inflammation and Implications for Treatment. McCaulley ME, Grush KA. International Journal of Alzheimer's Disease, 2015; 2015:515248. https://doi.org/10.1155/2015/515248. Epub 2015 Nov 17.
- Seeking a New Paradigm for Alzheimer's Disease: Considering the Roles of Inflammation, Blood-Brain Barrier Dysfunction, and Prion Disease. McCaulley ME, Grush KA. International Journal of Alzheimer's Disease, 2017; 2017:2438901. https://doi.org/10.1155/2017/2438901. Epub 2017 Dec 5.
- Autism spectrum disorder and mercury toxicity: Use of genomic and epigenetic methods to solve the etiologic puzzle. McCaulley ME. Acta Neurobiologiae Experimentalis (Wars), 2019; 79(2):113-125. https://doi.org/10.1101/2025.05.29.25328282
- Impaired Pathways of Detoxification and Risk of Alzheimer's Disease in Humans – Differential Gene Expression Studies via Gene Set Analysis. medRxiv preprint.
11. Alzheimer's Disease: New perspectives. preprints.org. https://www.preprints.org/manuscript/202507.0478/v1
About Sirius Neroscience, LLC
Our Vision
At Sirius we believe - Alzheimer's science and research has been unduly influenced by the Amyloid hypothesis. This has led to biotech spending of massive resources that should be redirected to more balanced areas that with adequate investment and research are more likely to lead to tangible results that will finally decrease the burden of Alzheimer's disease (AD). Our current focus is on:
-defining the role of environmental and endogenous toxins in neurodegeneration
-how to enhance the body's capability in excreting these toxins
-defining just what toxins are causing neurodegeneration
-defining and exploring the role of viral and other infections and ways to decrease the impact of those infection
-promoting the widespread adoption of risk factor assessment of AD risk
-promoting the adoption of focused prophylactic and treatment measures as directed by good quality research
-identifying granting opportunities that will be required to fund ongoing projects addressing the above
Alzheimer's Disease:
New Perspectives
Abstract July 2025
Alzheimer's disease (AD) continues being a scourge of modern humans. Undue emphasis on the Amyloid hypothesis has crowded out research on and use of alternate non-amyloid treatments.
This paper discusses the deficiencies of the amyloid hypothesis while recognizing the tangible though quite limited benefits of anti-amyloid treatments, even in the face of frequent and sometimes severe toxicities, with associated major expense.
I discuss the data suggesting a role of toxic exposures in AD risk. I also discuss a method of decreasing the impact of toxic exposures, and the early evidence of safety and potential for benefit in decreasing the impact of toxic exposures.
I discuss the risk of APOE alleles in AD risk, and the mechanisms by which this risk is created. The role of APOE in susceptibility to toxic exposures and infections is discussed.
The physiology of acetylcholine is discussed along with the rationale for increasing its levels through the inhibition of the enzyme that degrades it, acetylcholine-esterase (AChE). The new inhibitor of AChE, MSF, with its superior efficacy is discussed along with the hurdles in the MSF approval process.
I discuss the role of herpes simplex infections in AD risk and the means of mitigating this risk.
I discuss the role of herpes zoster (VZV) in chicken pox, shingles, and AD risk. Vaccine for limitation of that risk is discussed.
Traumatic brain injury as an etiology for AD is discussed.
The need for and means of risk stratification is discussed.
Possible means of AD prophylaxis in higher risk populations is discussed along with rationale for use of prophylaxis.
The concepts and methods of evaluation and treatment presented in this paper are straightforward, safe, inexpensive, with a significant probability of benefit, based on new perspectives.
Revolutionizing Medicine thought
Welcome to Sirius Brain
We are a biotechnology company dedicated to advancing science and improving lives. With cutting-edge research and a team of talented scientists, we strive to develop innovative solutions to some of the world's most pressing problems. Our mission is to make a positive impact on society through our work, and we are committed to excellence in all that we do.